Lu, S., Cho, B. C., Li, Z., Yang, B., Gregorc, V., Wu, L., Zhao, J., Loong, H. H., Chen, C., Li, H., Wang, S., Shen, Y., Fan, Z., Chen, J., Zhang, J., Johnson, M. L., Wang, A., Solomon, B., Chen, G. Z. J., Mok, T. S. (2026). Elisrasib (D3S-001), a next-generation GDP-bound KRAS G12C inhibitor, as first-line therapy for KRAS G12C mutation–positive non–small cell lung cancer (NSCLC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.8511